View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
October 24, 2018

NextCure begins Phase I/II trial of NC318 for solid tumours

NextCure has started a Phase I/II clinical trial of NC318 for the treatment of patients with advanced or metastatic solid tumours.

NextCure has started a Phase I/II clinical trial of NC318 for the treatment of patients with advanced or metastatic solid tumours.

In the Phase I dose-escalation portion of the trial, NextCure will investigate the safety and tolerability of NC318 in patients with advanced or metastatic solid tumours, and establish the maximum tolerated dose of NC318.

The trial’s Phase II will begin once the maximum tolerated dose is achieved and will evaluate the efficacy of NC318 in selected tumour types.

Its primary endpoint is the number of subjects with treatment-emergent adverse events, as assessed by common terminology criteria for adverse events v5.0 (CTCAE v5.0), and determining a maximum tolerated dose (MTD) or pharmacologically active dose (PAD).

The trial’s secondary endpoints include disease response, maximum llasma concentration (Cmax) of NC318, and others.

“Laboratory studies demonstrate that Siglec-15 modulates immune suppression in a manner independent of the PD-1/PD-L1 pathway.”

NextCure CMO Kevin Heller said: “Immunotherapies targeting T cell function have significantly improved patient outcomes, however a substantial proportion of patients do not respond to currently approved PD-1 or PD-L1 antibody therapies.

“Laboratory studies demonstrate that Siglec-15 modulates immune suppression in a manner independent of the PD-1/PD-L1 pathway, suggesting that NC318 may have the potential to be used in patients who do not express PD-L1.

“Blocking S15 with NC318 is expected to diminish immunosuppression and normalise the immune response, resulting in a clinically relevant anti-tumour immune response. A goal of our trial is to test that hypothesis.”

NC318 is an S15 antibody and has demonstrated an ability to block the negative effects of S15 in preclinical studies.

The immunomedicine has the potential to treat various cancer types.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena